Martin Edelman joined Fox Chase Cancer Center as chair of the Department of Hematology/Oncology.
He will also serve as deputy cancer center director for clinical research, leading the effort to integrate discoveries from the Translational Research Initiative into a strong investigator-initiated clinical trials program.
Edelman will collaborate with clinical, scientific, and administrative leadership to grow robust therapeutic, clinical research, and translational research programs in hematology and medical oncology while leading the department in evaluating emerging national trends in the delivery of cancer care.
Edelman comes to Fox Chase from the University of Maryland Greenebaum Comprehensive Cancer Center, where he served most recently as the head of the section of solid tumor oncology and associate director of the division of hematology/oncology. In addition, he was a professor of medicine and radiation oncology at the University of Maryland School of Medicine.
Edelman developed one of the most commonly used regimens for treating advanced lung cancer and working toward the development of new agents and biomarkers to personalize lung cancer therapy. He has a particular interest in approaches that integrate surgery, radiation, and chemotherapy in the management of lung cancer patients.
He serves on the Lung Cancer Committee of the Alliance, the Board of Directors of the Alliance for Clinical Trials in Oncology, and the Thoracic Malignancies Steering Committee of the National Cancer Institute’s Scientific Review Group. In addition, he is the Medical Oncology Co-chair for the Lung Cancer Committee of the Radiation Therapy Oncology Group.
He has been active within the American Society for Clinical Oncology and has chaired the lung cancer sections for the scientific and educational committees as well as a past member of the governmental affairs committee. As a member of the International Association for the Study of Lung Cancer, he has chaired the Career Development and Ethics Committees.
